Advanced Cancers Clinical Trial
Official title:
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
Primary Objective:
- Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18
fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in
calculating left ventricular ejection fraction (LVEF), end diastolic volume (EDV) and
end systolic volume (ESV).
Your doctor has ordered a PET/CT scan and a NM scan on you for routine care. By agreeing to
take part in this study, you will go through both of these procedures as you normally would.
For both imaging exams, you will be lying on your back. Every effort will be made to make
you as comfortable as possible. For theNM cardiac scan, you will be hooked up to a heart
monitor that will take a picture every time your heart beats. Your heart will be imaged from
several different views. This exam will take about 30 minutes.
The PET/CT cardiac scan will be done after completion of your normally scheduled PET/CT
scan. For this scan, you will be hooked to a heart monitor that records the beats of your
heart. While this monitor is attached, you will be imaged with the PET/CT scanner. The
PET/CT cardiac scan will take about 10-15 minutes after your PET/CT exam is completed.
Both imaging exams will provide a number that corresponds to the percent of blood pushed out
of the left ventricle of your heart during a resting state.
Taking part in this study should add between 10-15 additional minutes to your PET/CT visit.
This is due to the additional cardiac imaging time.
This is an investigational study. A total of up to 50 patients will take part in this study.
All will be enrolled at UTMDACC.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
| Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
| Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
| Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
| Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
| Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
| Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
| Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
| Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
| Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
| Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
| Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
| Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
| Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
| Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A | |
| Terminated |
NCT02521194 -
Occupational Therapy in Palliative Care
|
N/A |